Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

Real Chemistry has created an artificial intelligence-enabled platform to improve a manual, fragmented stage of the ...

INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

Taiho Pharmaceuticals, together with U.S.-based subsidiary Taiho Oncology, has inched closer to approval of another oral ...

Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...

The start-up, which deploys unmanned, reusable rockets into Earth’s low-orbit, secured another $251 million in a series D ...